FindTrial
Sign In

Diagnosis and Outcome of HLH in adult ICU patients

Hemophagocytic Lymphohistiocytosis in Critically ill Adult Patients : A Prospective Observational Multicentre Intensive Care Unit Study (MAS- ICU study) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112769
Enrollment
150
Registered
2026-06-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D899- Disorder involving the immune mechanism, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Pragati Jena
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All critically ill adult patients admitted to the ICU with a clinical suspicion of HLH

Exclusion criteria

Exclusion criteria: Age below 18 years Diagnosis of HLH 48 hours prior to ICU admission Known primary HLH

Design outcomes

Primary

MeasureTime frame
All cause mortality following the diagnosis of HLHTimepoint: 4 weeks—

Secondary

MeasureTime frame
To assess 90 days all cause mortality To evaluate clinical response to HLH specific therapiesTimepoint: 12 weeks—

Countries

India

Contacts

Public ContactDr Pragati Jena

IMS and SUM Hospital

pragatijena@soa.ac.in8939918185

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026